SUPRAX- cefixime powder, for suspension

SUPRAX by

Drug Labeling and Warnings

SUPRAX by is a Prescription medication manufactured, distributed, or labeled by Lupin Pharmaceuticals, Inc., LUPIN LIMITED. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    1.1 Uncomplicated Urinary Tract Infections

    SUPRAX is indicated in the treatment of adults and pediatric patients six months of age or older with uncomplicated urinary tract infections caused by susceptible isolates of Escherichia coli and Proteus mirabilis.

    1.2 Otitis Media

     SUPRAX is indicated in the treatment of adults and pediatric patients six months of age or older with otitis media caused by susceptible isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes. (Efficacy for Streptococcus pyogenes in this organ system was studied in fewer than 10 infections.)

    Note: For patients with otitis media caused by Streptococcus pneumoniae, overall response was approximately 10% lower for cefixime than for the comparator [see Clinical Studies (14)].

    1.3 Pharyngitis and Tonsillitis

    SUPRAX is indicated in the treatment of adults and pediatric patients six months of age or older with pharyngitis and tonsillitis caused by susceptible isolates of Streptococcus pyogenes. (Note: Penicillin is the usual drug of choice in the treatment of Streptococcus pyogenes infections. SUPRAX is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, data establishing the efficacy of SUPRAX in the subsequent prevention of rheumatic fever is not available.)

    1.4 Acute Exacerbations of Chronic Bronchitis

    SUPRAX is indicated in the treatment of adults and pediatric patients six months of age or older with acute exacerbations of chronic bronchitis caused by susceptible isolates of Streptococcus pneumoniae and Haemophilus influenzae.

    1.5 Uncomplicated Gonorrhea (cervical/urethral)

    SUPRAX is indicated in the treatment of adults and pediatric patients six months of age or older with uncomplicated gonorrhea (cervical/urethral) caused by susceptible isolates of Neisseria gonorrhoeae (penicillinase-and non-penicillinase-producing isolates).

    1.6 Usage

    To reduce the development of drug resistant bacteria and maintain the effectiveness of SUPRAX and other antibacterial drugs, SUPRAX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Adults

    The recommended dose of cefixime is 400 mg daily. This may be given as a 400 mg tablet or capsule daily or the 400 mg tablet may be split and given as one half tablet every 12 hours. For the treatment of uncomplicated cervical/urethral gonococcal infections, a single oral dose of 400 mg is recommended. The capsule and tablet may be administered without regard to food.

    In the treatment of infections due to Streptococcus pyogenes, a therapeutic dosage of cefixime should be administered for at least 10 days.

    2.2 Pediatric Patients (6 months or older)

    The recommended dose is 8 mg/kg/day of the suspension. This may be administered as a single daily dose or may be given in two divided doses, as 4 mg/kg every 12 hours.

    Note: A suggested dose has been determined for each pediatric weight range. Refer to Table 1. Ensure all orders that specify a dose in milliliters include a concentration, because SUPRAX for oral suspension is available in three different concentrations (100 mg/5 mL, 200 mg/5 mL, and 500 mg/5 mL).

    Table 1. Suggested doses for pediatric patients
  • * The preferred concentrations of oral suspension to use are 100 mg/5 mL or 200 mg/5 mL for pediatric patients in these weight ranges.
    		•
    PEDIATRIC DOSAGE CHART
    Doses are suggested for each weight range and rounded for ease of administration

    		SUPRAX (cefixime) for oral suspension
    		SUPRAX (cefixime) chewable tablet

    		100 mg/5 mL
    		200 mg/5 mL
    		500 mg/5 mL

    Patient Weight
    (kg)
    		Dose/Day 
    (mg)
    		Dose/Day 
    (mL)
    		Dose/Day 
    (mL)
    		Dose/Day 
    (mL)
    		Dose
    5 to 7.5*
    		50
    		2.5
    		--
    		--
    		--
    7.6 to 10*
    		80
    		4
    		2
    		--
    		--
    10.1 to 12.5
    		100
    		5
    		2.5
    		1
    		1 tablet of 100 mg
    12.6 to 20.5
    		150
    		7.5
    		4
    		1.5
    		1 tablet of 150 mg
    20.6 to 28
    		200
    		10
    		5
    		2
    		1 tablet of 200 mg
    28.1 to 33
    		250
    		12.5
    		6
    		2.5
    		1 tablet of 100 mg and 
    1 tablet of 150 mg
    33.1 to 40
    		300
    		15
    		7.5
    		3
    		2 tablets of 150 mg
    40.1 to 45
    		350
    		17.5
    		9
    		3.5
    		1 tablet of 150 mg and 
    1 tablet of 200 mg
    45.1 or greater
    		400
    		20
    		10
    		4
    		2 tablets of 200 mg

    Children weighing more than 45 kg or older than 12 years should be treated with the recommended adult dose. SUPRAX (cefixime) chewable tablets must be chewed or crushed before swallowing.

    Otitis media should be treated with the chewable tablets or suspension. Clinical trials of otitis media were conducted with the chewable tablets or suspension, and the chewable tablets or suspension results in higher peak blood levels than the tablet when administered at the same dose.

    Therefore, the tablet or capsule should not be substituted for the chewable tablets or suspension in the treatment of otitis media [see Clinical Pharmacology (12.3)].

    In the treatment of infections due to Streptococcus pyogenes, a therapeutic dosage of cefixime should be administered for at least 10 days.

    2.3 Renal Impairment

    SUPRAX may be administered in the presence of impaired renal function. Normal dose and schedule may be employed in patients with creatinine clearances of 60 mL/min or greater. Refer to Table 2 for dose adjustments for adults with renal impairment. Neither hemodialysis nor peritoneal dialysis removes significant amounts of drug from the body.

    Table 2. Doses for Adults with Renal Impairment
  • * The preferred concentrations of oral suspension to use are 200 mg/5 mL or 500 mg/5 mL for patients with this renal dysfunction
    		•
    Renal Dysfunction 
    		SUPRAX (cefixime) for oral suspension
    		Tablet
    		Chewable Tablet
    Creatinine Clearance (mL/min)
    		100 mg/5 mL
    		200 mg/5 mL
    		500 mg/5 mL
    		400 mg
    		200 mg

    		Dose/Day 
    (mL)
    		Dose/Day 
    (mL)
    		Dose/Day 
    (mL)
    		Dose/Day
    		Dose/Day
    60 or greater
    		Normal dose
    		Normal dose
    		Normal dose
    		Normal dose
    		Normal dose
    21 to 59*
    OR renal hemodialysis*
    		13
    		6.5
    		2.6
    		Not Appropriate
    		Not Appropriate
    20 or less 
    OR continuous peritoneal 
    dialysis 
    		8.6
    		4.4
    		1.8
    		0.5 tablet
    		1 tablet

    2.4 Reconstitution Directions for Oral Suspension

    Strength
    		Bottle Size
    		Reconstitution Directions
    100 mg/5 mL and 
    200 mg/5 mL
    		100 mL
    		To reconstitute, suspend with 68 mL water. 
    Method: Tap the bottle several times to loosen powder contents prior to reconstitution. 
    Add approximately half the total amount of water for reconstitution and shake well. 
    Add the remainder of water and shake well.
    100 mg/5 mL and 
    200 mg/5 mL
    		75 mL
    		To reconstitute, suspend with 51 mL water. 
    Method: Tap the bottle several times to loosen powder contents prior to reconstitution. 
    Add approximately half the total amount of water for reconstitution and shake well. 
    Add the remainder of water and shake well.
    100 mg/5 mL and 
    200 mg/5 mL
    		50 mL
    		To reconstitute, suspend with 34 mL water. 
    Method: Tap the bottle several times to loosen powder contents prior to reconstitution. 
    Add approximately half the total amount of water for reconstitution and shake well. 
    Add the remainder of water and shake well.
    200 mg/5 mL
    		37.5 mL
    		To reconstitute, suspend with 26 mL water. 
    Method: Tap the bottle several times to loosen powder contents prior to reconstitution. 
    Add approximately half the total amount of water for reconstitution and shake well. 
    Add the remainder of water and shake well.
    200 mg/5 mL
    		25 mL
    		To reconstitute, suspend with 17 mL water. 
    Method: Tap the bottle several times to loosen powder contents prior to reconstitution. 
    Add approximately half the total amount of water for reconstitution and shake well. 
    Add the remainder of water and shake well.
    500 mg/5 mL
    		20 mL
    		To reconstitute, suspend with 14 mL water. 
    Method: Tap the bottle several times to loosen powder contents prior to reconstitution. 
    Add approximately half the total amount of water for reconstitution and shake well. 
    Add the remainder of water and shake well.
    500 mg/5 mL
    		10 mL
    		To reconstitute, suspend with 8 mL water. 
    Method: Tap the bottle several times to loosen powder contents prior to reconstitution. 
    Add approximately half the total amount of water for reconstitution and shake well. 
    Add the remainder of water and shake well.

    After reconstitution, the suspension may be kept for 14 days either at room temperature, or under refrigeration, without significant loss of potency. Keep tightly closed. Shake well before using. Discard unused portion after 14 days.

  • 3 DOSAGE FORMS AND STRENGTHS

    SUPRAX is available for oral administration in the following dosage forms and strengths:

    • Film-coated tablets provide 400 mg of cefixime as trihydrate. These are white to off-white, film-coated, capsule shaped tablets with beveled edges and a divided score line on each side. The tablet is debossed with "SUPRAX" across one side and "LUPIN" across the other side.
    • Capsules provide 400 mg of cefixime as trihydrate. These are size "00EL" capsules with pink opaque cap and pink opaque body with "LU" on the cap and "U43" on the body in black ink. Capsules contain white to yellowish white granular powder.
    • Chewable tablets provide either 100 mg or 150 mg or 200 mg of cefixime as trihydrate. The 100 mg tablet is pink, round tablet, debossed with "SUPRAX 100" on one side and "LUPIN" on other side. The 150 mg tablet is pink, round tablet, debossed with "SUPRAX 150" on one side and "LUPIN" on other side. The 200 mg tablet is pink, round tablet, debossed with "SUPRAX 200" on one side and "LUPIN" on other side.
    • Powder for oral suspension, when reconstituted, provides either 100 mg/5 mL or 200 mg/5 mL or 500 mg/5 mL of cefixime as trihydrate. For 100 mg/5 mL and 200 mg/5 mL, the powder has an off white to pale yellow color and is strawberry flavored. For 500 mg/5 mL, the powder has an off white to cream color and is strawberry flavored.
  • 4 CONTRAINDICATIONS

    SUPRAX (cefixime) is contraindicated in patients with known allergy to cefixime or other cephalosporins.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Hypersensitivity Reactions

    Anaphylactic/anaphylactoid reactions (including shock and fatalities) have been reported with the use of cefixime.

    Before therapy with SUPRAX is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins, or other drugs. If this product is to be given to penicillin-sensitive patients, caution should be exercised because cross hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to SUPRAX occurs, discontinue the drug.

    5.2 Clostridium difficile-Associated Diarrhea

    Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including SUPRAX, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

    C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing isolates of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

    If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

    5.3 Dose Adjustment in Renal Impairment

    The dose of SUPRAX should be adjusted in patients with renal impairment as well as those undergoing continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD). Patients on dialysis should be monitored carefully [see Dosage and Administration (2)].

    5.4 Coagulation Effects

    Cephalosporins, including SUPRAX, may be associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated.

    5.5 Development of Drug-Resistant Bacteria

    Prescribing SUPRAX (cefixime) in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

    5.6 Risk in Patients with Phenylketonuria

    Phenylalanine can be harmful to patients with phenylketonuria (PKU). SUPRAX chewable tablets contain aspartame, a source of phenylalanine. Each 100 mg, 150 mg and 200 mg strength contains 3.3 mg, 5 mg and 6.7 mg of phenylalanine, respectively. Before prescribing SUPRAX chewable tablets in a patient with PKU, consider the combined daily amount of phenylalanine from all sources, including SUPRAX chewable tablets.

  • 6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    The most commonly seen adverse reactions in U.S. trials of the tablet formulation were gastrointestinal events, which were reported in 30% of adult patients on either the twice daily or the once daily regimen. Five percent (5%) of patients in the U.S. clinical trials discontinued therapy because of drug-related adverse reactions. Individual adverse reactions included diarrhea 16%, loose or frequent stools 6%, abdominal pain 3%, nausea 7%, dyspepsia 3%, and flatulence 4%. The incidence of gastrointestinal adverse reactions, including diarrhea and loose stools, in pediatric patients receiving the suspension was comparable to the incidence seen in adult patients receiving tablets.

    6.2 Post-marketing Experience

    The following adverse reactions have been reported following the post-approval use of cefixime. Incidence rates were less than 1 in 50 (less than 2%).

    Gastrointestinal

    Several cases of documented pseudomembranous colitis were identified in clinical trials. The onset of pseudomembranous colitis symptoms may occur during or after therapy.

    Hypersensitivity Reactions

    Anaphylactic/anaphylactoid reactions (including shock and fatalities), skin rashes, urticaria, drug fever, pruritus, angioedema, and facial edema. Erythema multiforme, Stevens-Johnson syndrome, and serum sickness-like reactions have been reported.

    Hepatic

    Transient elevations in SGPT, SGOT, alkaline phosphatase, hepatitis, jaundice.

    Renal

    Transient elevations in BUN or creatinine, acute renal failure.

    Central Nervous System

    Headaches, dizziness, seizures.

    Hemic and Lymphatic System

    Transient thrombocytopenia, leukopenia, neutropenia, prolongation in prothrombin time, elevated LDH, pancytopenia, agranulocytosis, and eosinophilia.

    Abnormal Laboratory Tests

    Hyperbilirubinemia.

    Other Adverse Reactions

    Genital pruritus, vaginitis, candidiasis, toxic epidermal necrolysis.

    Adverse Reactions Reported for Cephalosporin-class Drugs

    Allergic reactions, superinfection, renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, hemorrhage, and colitis.

    Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced [see Dosage and Administration (2) and Overdosage (10)]. If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.

  • 7 DRUG INTERACTIONS

    7.1 Carbamazepine

    Elevated carbamazepine levels have been reported in postmarketing experience when cefixime is administered concomitantly. Drug monitoring may be of assistance in detecting alterations in carbamazepine plasma concentrations.

    7.2 Warfarin and Anticoagulants

    Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.

    7.3 Drug/Laboratory Test Interactions

    A false-positive reaction for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide.

    The administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest®**, Benedict's solution, or Fehling's solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix®** or TesTape®**) be used. A false-positive direct Coombs test has been reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug.

    **   Clinitest® and Clinistix® are registered trademarks of Ames Division, Miles Laboratories, Inc. Tes-Tape® is a registered trademark of Eli Lilly and Company.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Pregnancy Category B

    Reproduction studies have been performed in mice and rats at doses up to 40 times the human dose and have revealed no evidence of harm to the fetus due to cefixime. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

    8.2 Labor and Delivery

    Cefixime has not been studied for use during labor and delivery. Treatment should only be given if clearly needed.

    8.3 Nursing Mothers

    It is not known whether cefixime is excreted in human milk. Consideration should be given to discontinuing nursing temporarily during treatment with this drug.

    8.4 Pediatric Use

    Safety and effectiveness of cefixime in children aged less than six months old have not been established. The incidence of gastrointestinal adverse reactions, including diarrhea and loose stools, in the pediatric patients receiving the suspension, was comparable to the incidence seen in adult patients receiving tablets.

    8.5 Geriatric Use

    Clinical studies did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. A pharmacokinetic study in the elderly detected differences in pharmacokinetic parameters [see Clinical Pharmacology (12.3)]. These differences were small and do not indicate a need for dosage adjustment of the drug in the elderly.

    8.6 Renal Impairment

    The dose of cefixime should be adjusted in patients with renal impairment as well as those undergoing continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD). Patients on dialysis should be monitored carefully [see Dosage and Administration (2.3)].

  • 10 OVERDOSAGE

    Gastric lavage may be indicated; otherwise, no specific antidote exists. Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis. Adverse reactions in small numbers of healthy adult volunteers receiving single doses up to 2 g of cefixime did not differ from the profile seen in patients treated at the recommended doses.

  • 11 DESCRIPTION

    Cefixime is a semisynthetic, cephalosporin antibacterial for oral administration. Chemically, it is (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-vinyl-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid, 72-(Z)-[O-(carboxy methyl) oxime] trihydrate.

    Molecular weight = 507.50 as the trihydrate. Chemical Formula is C16H15N5O7S2.3H2O

    The structural formula for cefixime is:

    Cefixime USP
    • Inactive ingredients contained in SUPRAX® (cefixime) 400 mg tablets USP are: dibasic calcium phosphate, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized starch, titanium dioxide, and triacetin.
    • Inactive ingredients contained in SUPRAX® (cefixime) 400 mg capsules are: colloidal silicon dioxide, crospovidone, low substituted hydroxy propyl cellulose, magnesium stearate, and mannitol. The capsule shell contains the following inactive ingredients: ferric oxide black, ferric oxide red, gelatin, potassium hydroxide, propylene glycol, shellac, sodium lauryl sulfate, and titanium dioxide.
    • Inactive ingredients contained in SUPRAX® (cefixime) 100 mg or 150 mg or 200 mg chewable tablets are: aspartame, colloidal silicon dioxide, crospovidone, FD&C Red # 40 Aluminium Lake, low substituted hydroxypropyl cellulose, magnesium stearate, mannitol, fantasy flavor permaseal, and tutti frutti flavor.
    • Inactive ingredients contained in SUPRAX® (cefixime) powder for oral suspension USP are: colloidal silicon dioxide, sodium benzoate, strawberry flavor, sucralose (only in 500 mg/5 mL strength), sucrose, and xanthan gum.
  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Cefixime is a semisynthetic cephalosporin antibacterial drug [see Microbiology (12.4)].

    12.3 Pharmacokinetics

    SUPRAX chewable tablets are bioequivalent to oral suspension.

    SUPRAX tablets and suspension, given orally, are about 40% to 50% absorbed whether administered with or without food; however, time to maximal absorption is increased approximately 0.8 hours when administered with food. A single 200 mg tablet of cefixime produces an average peak serum concentration of approximately 2 mcg/mL (range 1 to 4 mcg/mL); a single 400 mg tablet produces an average peak concentration of approximately 3.7 mcg/mL (range 1.3 to 7.7 mcg/mL). The oral suspension produces average peak concentrations approximately 25% to 50% higher than the tablets, when tested in normal adult volunteers. Two hundred and 400 mg doses of oral suspension produce average peak concentrations of 3 mcg/mL (range 1 to 4.5 mcg/mL) and 4.6 mcg/mL (range 1.9 to 7.7 mcg/mL), respectively, when tested in normal adult volunteers. The area under the time versus concentration curve (AUC) is greater by approximately 10% to 25% with the oral suspension than with the tablet after doses of 100 to 400 mg, when tested in normal adult volunteers. This increased absorption should be taken into consideration if the oral suspension is to be substituted for the tablet. Because of the lack of bioequivalence, tablets should not be substituted for oral suspension in the treatment of otitis media [see Dosage and Administration (2)]. Cross-over studies of tablet versus suspension have not been performed in children.

    The 400 mg capsule is bioequivalent to the 400 mg tablet under fasting conditions. However, food reduces the absorption following administration of the capsule by approximately 15% based on AUC and 25% based on Cmax.

    Peak serum concentrations occur between 2 and 6 hours following oral administration of a single 200 mg tablet, a single 400 mg tablet or 400 mg of cefixime suspension. Peak serum concentrations occur between 2 and 5 hours following a single administration of 200 mg of suspension. Peak serum concentrations occur between 3 and 8 hours following oral administration of a single 400 mg capsule.

    Distribution

    Serum protein binding is concentration independent with a bound fraction of approximately 65%. In a multiple dose study conducted with a research formulation which is less bioavailable than the tablet or suspension, there was little accumulation of drug in serum or urine after dosing for 14 days. Adequate data on CSF levels of cefixime are not available.

    Metabolism and Excretion

    There is no evidence of metabolism of cefixime in vivo. Approximately 50% of the absorbed dose is excreted unchanged in the urine in 24 hours. In animal studies, it was noted that cefixime is also excreted in the bile in excess of 10% of the administered dose. The serum half-life of cefixime in healthy subjects is independent of dosage form and averages 3 to 4 hours but may range up to 9 hours in some normal volunteers.

    Special Populations

    Geriatrics: Average AUCs at steady state in elderly patients are approximately 40% higher than average AUCs in other healthy adults. Differences in the pharmacokinetic parameters between 12 young and 12 elderly subjects who received 400 mg of cefixime once daily for 5 days are summarized as follows:

  • * Difference between age groups was significant. (p<0.05)
    		•
    Pharmacokinetic Parameters (mean ± SD) for Cefixime in Both Young & Elderly Subjects
    Pharmacokinetic parameter
    		Young
    		Elderly
    Cmax (mg/L)
    		4.74 ± 1.43
    		5.68 ± 1.83
    Tmax (h)*
    		3.9 ± 0.3
    		4.3 ± 0.6
    AUC (mg.h/L)*
    		34.9 ± 12.2
    		49.5 ± 19.1
    T½ (h)*
    		3.5 ± 0.6
    		4.2 ± 0.4
    Cave (mg/L)*
    		1.42 ±0.50
    		1.99 ± 0.75

    However, these increases were not clinically significant [see Dosage and Administration (2)].

    Renal Impairment: In subjects with moderate impairment of renal function (20 to 40 mL/min creatinine clearance), the average serum half-life of cefixime is prolonged to 6.4 hours. In severe renal impairment (5 to 20 mL/min creatinine clearance), the half-life increased to an average of 11.5 hours. The drug is not cleared significantly from the blood by hemodialysis or peritoneal dialysis. However, a study indicated that with doses of 400 mg, patients undergoing hemodialysis have similar blood profiles as subjects with creatinine clearances of 21 to 60 mL/min.

    12.4 Microbiology

    Mechanism of Action

    As with other cephalosporins, the bactericidal action of cefixime results from inhibition of cell wall synthesis. Cefixime is stable in the presence of certain beta-lactamase enzymes. As a result, certain organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases may be susceptible to cefixime.

    Resistance

    Resistance to cefixime in isolates of Haemophilus influenzae and Neisseria gonorrhoeae is most often associated with alterations in penicillin-binding proteins (PBPs). Cefixime may have limited activity against Enterobacteriaceae producing extended spectrum beta-lactamases (ESBLs). Pseudomonas species, Enterococcus species, strains of Group D streptococci, Listeria monocytogenes, most strains of staphylococci (including methicillin-resistant strains), most strains of Enterobacter species, most strains of Bacteroides fragilis, and most strains of Clostridium species are resistant to cefixime.

    Antimicrobial Activity

    Cefixime has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections [see Indications and Usage (1)].

    Gram-positive Bacteria

    Streptococcus pneumoniae

    Streptococcus pyogenes

    Gram-negative Bacteria

    Escherichia coli

    Haemophilus influenzae

    Moraxella catarrhalis

    Neisseria gonorrhoeae

    Proteus mirabilis

    The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for cefixime against isolates of similar genus or organism group. However, the efficacy of cefixime in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.

    Gram-positive Bacteria

    Streptococcus agalactiae

    Gram-negative Bacteria

    Citrobacter amalonaticus

    Citrobacter diversus

    Haemophilus parainfluenzae

    Klebsiella oxytoca

    Klebsiella pneumoniae

    Pasteurella multocida

    Proteus vulgaris

    Providencia species

    Salmonella species

    Serratia marcescens

    Shigella species

    Susceptibility Testing

    For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Lifetime studies in animals to evaluate carcinogenic potential have not been conducted. Cefixime did not cause point mutations in bacteria or mammalian cells, DNA damage, or chromosome damage in vitro and did not exhibit clastogenic potential in vivo in the mouse micronucleus test. In rats, fertility and reproductive performance were not affected by cefixime at doses up to 25 times the adult therapeutic dose.

  • 14 CLINICAL STUDIES

    Comparative clinical trials of otitis media were conducted in nearly 400 children between the ages of 6 months to 10 years. Streptococcus pneumoniae was isolated from 47% of the patients, Haemophilus influenzae from 34%, Moraxella catarrhalis from 15% and S. pyogenes from 4%.

    The overall response rate of Streptococcus pneumoniae to cefixime was approximately 10% lower and that of Haemophilus influenzae or Moraxella catarrhalis approximately 7% higher (12% when beta-lactamase positive isolates of H. influenzae are included) than the response rates of these organisms to the active control drugs.

    In these studies, patients were randomized and treated with either cefixime at dose regimens of 4 mg/kg twice a day or 8 mg/kg once a day, or with a comparator. Sixty-nine to 70% of the patients in each group had resolution of signs and symptoms of otitis media when evaluated 2 to 4 weeks post-treatment, but persistent effusion was found in 15% of the patients. When evaluated at the completion of therapy, 17% of patients receiving cefixime and 14% of patients receiving effective comparative drugs (18% including those patients who had Haemophilus influenzae resistant to the control drug and who received the control antibacterial drug) were considered to be treatment failures. By the 2 to 4 week follow-up, a total of 30%-31% of patients had evidence of either treatment failure or recurrent disease.

    (a)Number eradicated/number isolated.

    (b)An additional 20 beta-lactamase positive isolates of Haemophilus influenzae were isolated, but were excluded from this analysis because they were resistant to the control antibacterial drug. In nineteen of these, the clinical course could be assessed and a favorable outcome occurred in 10. When these cases are included in the overall bacteriological evaluation of therapy with the control drugs, 140/185 (76%) of pathogens were considered to be eradicated.
    Bacteriological Outcome of Otitis Media at Two to Four Weeks Post-Therapy Based on Repeat Middle Ear Fluid Culture or Extrapolation from Clinical Outcome
    Organism
    		Cefixime(a)
    4 mg/kg BID
    		Cefixime(a)
    8 mg/kg QD
    		Control(a)
    drugs
    Streptococcus pneumoniae
    		48/70 (69%)
    		18/22 (82%)
    		82/100 (82%)
    Haemophilus influenzae
    beta-lactamase negative
    		24/34 (71%)
    		13/17 (76%)
    		23/34 (68%)
    Haemophilus influenzae
    beta-lactamase positive
    		17/22 (77%)
    		9/12 (75%)
    		1/1 (b)
    Moraxella catarrhalis
    		26/31 (84%)
    		5/5
    		18/24 (75%)
    S. pyogenes
    		5/5
    		3/3
    		6/7
    All Isolates
    		120/162 (74%)
    		48/59 (81%)
    		130/166 (78%)
  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    SUPRAX® is available for oral administration in following dosage forms, strengths and packages listed in the table below:

    Dosage Form
    		Strength
    		Description
    		Package Size
    		NDC Code
    		Storage


    		White to off-white, 
    film-coated, capsule 
    shaped tablets with 
    beveled edges and 
    		Bottles of 
    10 tablets
    		27437-201-10
    SUPRAX® (cefixime) tablets USP
    		400 mg
    		a divided score 
    line on each side, 
    debossed with “SUPRAX” 
    across one side 
    		Bottle of 
    50 tablets
    		27437-201-08
    		Store at 20 to 25°C 
    (68 to 77°F) 
    [See USP Controlled 
    Room Temperature].


    		and “LUPIN” across 
    other side, containing 
    400 mg of cefixime
     as the trihydrate.
    		Bottle of 
    100 tablets
    		27437-201-01
    SUPRAX® (cefixime) capsules
    		400 mg
    		Size “00EL” capsules with 
    pink opaque cap and pink 
    opaque body, imprinted 
    with “LU” on cap and 
    “U43” on body in black 
    		Bottle of 
    50 capsules
    		27437-208-08
    		Store at 20 to 25°C 
    (68 to 77°F) 
    [See USP Controlled 
    Room Temperature].


    		ink, containing white to 
    yellowish white granular 
    powder containing 
    400 mg of cefixime as the 
    trihydrate.
    		Unit Dose 
    Package of 10
    (1 blister of 
    10 capsules)
    		27437-208-11



    		Bottles of 
    10 tablets
    		27437-203-10

    		100 mg
    		Pink, round tablet, 
    debossed with “SUPRAX 100” 
    on one side and “LUPIN” 
    on other side.
    		Bottle of 
    50 tablets
    		27437-203-08



    		Unit Dose 
    Package of 10
    (1 blister of 
    10 tablets)
    		27437-203-11



    		Bottles of 
    10 tablets
    		27437-204-10
    SUPRAX® (cefixime) chewable tablets
    		150 mg
    		Pink, round tablet, 
    debossed with “SUPRAX 150” 
    on one side and “LUPIN” 
    on other side.
    		Bottle of 
    50 tablets
    		27437-204-08
    		Store at 20 to 25°C 
    (68 to 77°F) 
    [See USP Controlled 
    Room Temperature].



    		Unit Dose 
    Package of 10
    (1 blister of 
    10 tablets)
    		27437-204-11



    		Bottles of 
    10 tablets
    		27437-205-10

    		200 mg
    		Pink, round tablet, 
    debossed with “SUPRAX 200” 
    on one side and “LUPIN” 
    on other side.
    		Bottle of 
    50 tablets
    		27437-205-08



    		Unit Dose 
    Package of 10
    (1 blister of 
    10 tablets)
    		27437-205-11



    		Off-white to pale 
    yellow colored powder. 
    After reconstituted as 
    		Bottle of 
    50 mL
    		68180-202-03
    		 

    		100 mg/5 mL
    		directed, each 5 mL of 
    reconstituted suspension 
    contains 100 mg of 
    		Bottle of 
    75 mL
    		68180-202-02
    		 


    		cefixime as the trihydrate.
    		Bottle of 
    100 mL
    		68180-202-01



    		Bottle of 
    25 mL
    		27437-206-05



    		Bottle of 
    37.5 mL
    		27437-206-06
    		Prior to reconstitution: 
    Store drug powder at
    SUPRAX® (cefixime) for oral suspension USP
    		200 mg/5 mL
    		Off-white to pale 
    yellow colored powder. 
    After reconstituted as 
    directed, each 5 mL of
    		Bottle of 
    50 mL
    		27437-206-03
    		20 to 25°C (68 to 77°F) 
    [See USP Controlled 
    Room Temperature].


    		reconstituted suspension 
    contains 200 mg of 
    cefixime as the trihydrate.
    		Bottle of 
    75 mL
    		27437-206-02
    		After reconstitution: 
    Store at room temperature 
    or under refrigeration.
    Keep tightly closed.



    		Bottle of 
    100 mL
    		27437-206-01

    		500 mg/5 mL
    		Off white to cream 
    colored powder forming 
    off-white to pale yellow 
    suspension with 
    characteristic fruity odor 
    		Bottle of 
    10 mL
    		27437-207-02


    		on constitution. After 
    reconstituted as directed,
    each mL of reconstituted 
    suspension contains 
    100 mg of cefixime 
    as the trihydrate.
    		Bottle of 
    20 mL
    		27437-207-03
  • 17 PATIENT COUNSELING INFORMATION

    17.1 Information for Patients

    Counsel patients that antibacterial drugs, including cefixime, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When cefixime is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefixime for oral suspension or cefixime chewable tablets or other antibacterial drugs in the future.

    Counsel patients with phenylketonuria that SUPRAX chewable tablets contain aspartame, a source of phenylalanine as follows: Each SUPRAX chewable tablet contains 3.3 mg, 5 mg and 6.7 mg of phenylalanine per 100 mg, 150 mg and 200 mg strength, respectively.

    Advise patients that diarrhea is a common problem caused by antibacterial drugs which usually ends when the antibacterial drug is discontinued. Sometimes after starting treatment with antibacterial drugs, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial drug. If this occurs, patients should contact their physician as soon as possible.

    Products
    		Manufactured for:
    		Manufactured by:
    SUPRAX ® (cefixime) tablets, 400 mg
    SUPRAX ® (cefixime) capsules, 400 mg
    SUPRAX ® (cefixime) chewable tablets, 100 mg, 150 mg and 200 mg
    		 Lupin Pharma
    Baltimore, Maryland 21202
    United States.
    SUPRAX ® (cefixime) for oral suspension, 200 mg/5 mL
    		 Lupin Limited
    Mandideep 462 046
    India.
    SUPRAX ® (cefixime) for oral suspension, 500 mg/5 mL
    SUPRAX ® (cefixime) for oral suspension, 100 mg/5 mL
    		 Lupin Pharmaceuticals, Inc.
    Baltimore, Maryland 21202
    United States

    ID#: 254614

  • PRINCIPAL DISPLAY PANEL

    SUPRAX® CEFIXIME FOR ORAL SUSPENSION USP

    100 mg/5 mL

    Rx only

    NDC: 68180-202-03: Bottle of 50 mL

    SUPRAX CEFIXIME FOR ORAL SUSPENSION USP 100 mg/5 mL Rx only NDC: <a href=/NDC/68180-202-03>68180-202-03</a>: Bottle of 50 mL

    SUPRAX® CEFIXIME FOR ORAL SUSPENSION USP

    100 mg/5 mL

    Rx only

    NDC: 68180-202-04: Bottle of 10 mL (Physician Sample Pack)

    NDC: 68180-202-05: Carton for 10 mL x 6 Bottles (Physician Sample Pack)

    SUPRAX CEFIXIME FOR ORAL SUSPENSION USP 100 mg/5 mL Rx only NDC: <a href=/NDC/68180-202-04>68180-202-04</a>: Bottle of 10 mL (Physician Sample Pack)
    SUPRAX CEFIXIME FOR ORAL SUSPENSION USP 100 mg/5 mL Rx only NDC: <a href=/NDC/68180-202-05>68180-202-05</a>: Carton for 10 mL x 6 Bottles (Physician Sample Pack
  • INGREDIENTS AND APPEARANCE
    SUPRAX 
    cefixime powder, for suspension
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 68180-202
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CEFIXIME (UNII: 97I1C92E55) (CEFIXIME ANHYDROUS - UNII:XZ7BG04GJX) CEFIXIME ANHYDROUS100 mg  in 5 mL
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    SODIUM BENZOATE (UNII: OJ245FE5EU)  
    STRAWBERRY (UNII: 4J2TY8Y81V)  
    SUCROSE (UNII: C151H8M554)  
    XANTHAN GUM (UNII: TTV12P4NEE)  
    Product Characteristics
    ColorWHITE (off-white to pale yellow) Score    
    ShapeSize
    FlavorImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 68180-202-056 in 1 CARTON03/01/2004
    1NDC: 68180-202-0410 mL in 1 BOTTLE; Type 0: Not a Combination Product
    2NDC: 68180-202-0350 mL in 1 BOTTLE; Type 0: Not a Combination Product03/01/2004
    3NDC: 68180-202-0275 mL in 1 BOTTLE; Type 0: Not a Combination Product03/01/2004
    4NDC: 68180-202-01100 mL in 1 BOTTLE; Type 0: Not a Combination Product03/01/2004
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA06512903/01/2004
    Labeler - Lupin Pharmaceuticals, Inc. (089153071)
    Registrant - LUPIN LIMITED (675923163)
    Establishment
    NameAddressID/FEIBusiness Operations
    LUPIN LIMITED725504448MANUFACTURE(68180-202)

    • Trademark Results [SUPRAX]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    SUPRAX
    SUPRAX
    86164468 4660961 Live/Registered
    Waterbrands, LLC
    2014-01-13
    SUPRAX
    SUPRAX
    73707543 1500158 Dead/Cancelled
    AMERICAN CYANAMID COMPANY
    1988-01-25
    SUPRAX
    SUPRAX
    73604097 1456050 Live/Registered
    AMERICAN CYANAMID COMPANY
    1986-06-13
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.